• Allarity Therapeutics announced a Trial-in-Progress poster for its ongoing Phase 2 stenoparib study in advanced platinum-resistant or platinum-ineligible ovarian cancer.
• The poster was presented June 18, 2026 at the ESMO Gynaecological Cancers Congress in Copenhagen.
• No results were presented; the disclosure focused on study rationale and design, with no new clinical outcomes.
• The trial aims to evaluate whether stenoparib can deliver durable clinical benefit in a hard-to-treat ovarian cancer population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180800PRIMZONEFULLFEED1001188404) on June 18, 2026, and is solely responsible for the information contained therein.